Immunome, Inc. (IMNM)
PHARMACEUTICAL PREPARATIONS
Immunome, Inc. (IMNM) is listed on Nasdaq, where it has traded since October 2, 2020.
- Listed On
- Nasdaq
- Listed Since
- October 2, 2020
- Employees
- 177
- Market Cap
- $2.2B
About Immunome, Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 191 institutions reported holding IMNM, with 117.5 million shares worth $2.5 billion in aggregate. The largest reported holder was T. Rowe Price, with 21.5 million shares worth $454.5 million. Of the 5 largest holders listed below, all 5 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| T. Rowe Price | 21,450,112 | $455M | Added 11.59% |
| FMR | 16,987,553 | $360M | Added 0.1% |
| BlackRock | 8,805,492 | $187M | Added 7.8% |
| Vanguard | 6,795,849 | $144M | Added 8.11% |
| State Street | 5,494,625 | $116M | Added 1.75% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is IMNM?
Immunome, Inc. (IMNM) is listed on Nasdaq, where it has traded since October 2, 2020.
Who are the largest institutional holders of IMNM?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of IMNM were T. Rowe Price, FMR and BlackRock.
How many institutions own IMNM?
191 institutions reported a position in IMNM for the quarter ended June 30, 2026, worth $2.5 billion in total.
Did institutions buy or sell IMNM last quarter?
Of the 5 largest reported holders, all 5 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for IMNM.
Every reported institutional holder, plus insider and congressional trades in IMNM, on SentiSense.